Hologic to Acquire Biotheranostics for ~$230M

 Hologic to Acquire Biotheranostics for ~$230M

Hologic to Acquire Biotheranostics for ~$230M

Shots:

  • Hologic acquires Biotheranostics to speed up its entry in the oncology market. The transaction is expected to be completed in Feb’2021
  • The acquisition will provide Hologic access to Biotheranostics’ CLIA lab and will aid in accelerating market development for novel tests
  • The acquisition allows Hologic to leverage commercial capabilities and expertise in molecular diagnostics automation to accelerate growth and deliver more personalized treatment for women

Click here ­to­ read full press release/ article | Ref: Business Wire | Image: Business Wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post